Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion, Quest Ink Deal to Sell OVA1 in India

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Vermillion today announced an agreement with Quest Diagnostics for the launch of the OVA1 ovarian cancer test in India.

The two firms are targeting the launch for the second quarter. In a statement, Gail Page, president and CEO of Austin, Texas-based Vermillion said that with 350 million women, India is an "outstanding market opportunity. … Vermillion is now poised for growth both domestically and internationally as we continue to develop our international strategy in concert with the efforts already underway in the US."

Quest already was marketing OVA1, which received clearance from the US Food and Drug Administration in September 2009, in the US. The test was the first protein-based in vitro diagnostic multivariate index assay to receive such approval.

Financial and other terms of today's deal were not disclosed.

Quest operates a 65,000 square-foot facility in Gurgaon, in the National Capital Region of India, that offers more than 700 tests using advanced technology and quality standards that comply with global best practices, Vermillion said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.